ENE GPW Periodic report · PAP Biznes
Enel-Med SA (ENE) · Q1 2026 results
Share price: 19.90 zł · 2026-11-10
Results Q1 2026 vs Q1 2025 · year over year · published 21 May 2026 and 29 May 2025
Net income down 84.2% year on year. The language turned more cautious.
Only a basic analysis is available for this company at the moment.
1 · Numbers
−84.2%
Net income vs Q1 2025
Net income 971.0K vs 6.2M
Revenue +15.2%
2 · How the report reads
More cautious
Language tone vs last period
Report language: typical for a company report — more cautious than in Q1 2025.
Weak signal: formal report language, not a call.
3 · What stood out Nothing unusual flagged this period.
Read between the lines
No major shifts flagged this period.
Tone
How upbeat the language was, compared with other companiesiTone counts positive minus negative finance words, adjusted for length. Executives mostly speak positively, so the labels compare each call with every company's latest call: “typical” is the middle third, “very upbeat” the top tenth, “cautious” the bottom tenth.. Dot: Q1 2026. Ring: Q1 2025.
Typical for a company report — more cautious than in Q1 2025. Periodic reports carry legally required risk wording, so their tone moves little and is a weak signal.
Sentences that drove the tone
“The Company also views marketing automation and e-commerce platforms as a significant investment area aimed at increasing online sales and improving the efficiency of marketing budget utilization.”
“Consequently, the Company is investing in new technologies and planning the development of teleinformatics systems aimed at further improving customer service and optimizing costs – including the further development of the mobile application, the medical system, or...”
“Due to the complexity of these factors, however, their impact on the Company's future financial results is difficult to predict.”
Full figures
PLN · PAP Biznes report (2026-05-21)
| Metric | Q1 2026 | Q1 2025 | Change |
|---|---|---|---|
| Revenue | 235.7M | 204.7M | +15.2% |
| Gross profit | 22.3M | 18.2M | +22.2% |
| Operating income | 8.0M | 6.1M | +29.7% |
| Net income | 971.0K | 6.2M | −84.2% |
| P/E today 43.3 | 42.4 | 38.5 | +3.9 |
Topics
Topics are drawn from the full report text, not management commentary.
Most discussed now
- The Management Board of the Company does not foresee that the new standards and amendments to the currently applicable standards could have…
- The Company's financial results are characterized by high volatility over time.
- The increase in interest rates causes an increase in the Company's financing costs, and as a result, a decrease in margins.
- This impact includes both direct service costs (including medical personnel salaries and medical supplies) as well as indirect costs…
- These actions constituted another step towards building a comprehensive offer in the field of orthopedics and sports medicine, meeting the…
Faded since Q1 2025
- Fading The marketing activities conducted by the Company were aimed at health education, which constituted an important element of building…
Latest announcements
Official filings, newest first.
- Incydent bezpieczeństwa IT i naruszenia poufności danych Centrum Medyczne ENEL-MED S.A. - uzupełnienie · ESPI 18/2026
- Incydent bezpieczeństwa IT i naruszenia poufności danych Centrum Medyczne ENEL-MED S.A. · ESPI 17/2026
- Half-year report · ESPI periodic
- RR · ESPI
- Korekta raportu okresowego za rok 2025 · ESPI 16/2026
- Zawarcie aneksu do umowy o linię wielocelową dla klienta korporacyjnego z Credit Agricole Bank Polska S.A. · ESPI 15/2026
- Powołanie członków Rady Nadzorczej · ESPI 14/2026
- Wykaz akcjonariuszy posiadających co najmniej 5% głosów na Zwyczajnym Walnym Zgromadzeniu Akcjonariuszy zwołanym na dzień 10 czerwca 2026 r. · ESPI 13/2026